Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
03 Marzo 2008 - 9:02PM
PR Newswire (US)
GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- Iomai
Corporation (NASDAQ:IOMI) today announced that it will release
fourth quarter and year-end 2007 financial results before the
markets open and hold a conference call and live webcast to discuss
corporate and clinical progress on Thursday, March 6, 2008 at 1:30
p.m. Eastern Time. Conference Call Details To access the live
conference call on Thursday, March 6 at 1:30 p.m. Eastern Time via
phone, please dial 866-578-5784 from the United States and Canada
or +1-617-213-8056 internationally. The conference ID is 87233725.
Please dial in approximately 10 minutes prior to the start of the
call. A telephone replay will be available beginning approximately
one hour after the call through March 10 and may be accessed by
dialing 888-286-8010 from the United States and Canada or
+1-617-801-6888 internationally. The replay passcode is 74369365.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
Company's website at http://www.iomai.com/. Please connect to the
web site at least 15 minutes prior to the call to allow for any
software download that may be necessary. The webcast is also being
distributed through the Thomson StreetEvents Network. Individual
investors can listen to the call at http://www.earnings.com/,
Thomson's individual investor portal, powered by StreetEvents.
Institutional investors can access the call via Thomson
StreetEvents (http://www.streetevents.com/), a password-protected
event management site. About Iomai Corporation Iomai Corporation
discovers and develops vaccines and immune system stimulants,
delivered via a novel, needle-free technology called transcutaneous
immunization (TCI). TCI taps into the unique benefits of a major
group of antigen-presenting cells found in the outer layers of the
skin (Langerhans cells) to generate an enhanced immune response.
Iomai is leveraging TCI to enhance the efficacy of existing
vaccines, develop new vaccines that are viable only through
transcutaneous administration and expand the global vaccine market.
Iomai currently has four product candidates in development: three
targeting influenza and pandemic flu and one to prevent travelers'
diarrhea. For more information on Iomai, please visit
http://www.iomai.com/. DATASOURCE: Iomai Corporation CONTACT:
Russell P. Wilson, Senior Vice President, Chief Financial Officer
and General Counsel of Iomai Corporation, +1-301-556-4478, ; or
Brian Reid of WeissComm Partners, Inc., +1-703-402-3626, , for
Iomai Corporation Web site: http://www.iomai.com/
Copyright
Grafico Azioni Iomai Corp (MM) (NASDAQ:IOMI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Iomai Corp (MM) (NASDAQ:IOMI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Iomai Corp (MM) (NASDAQ): 0 articoli recenti
Più Iomai (MM) Articoli Notizie